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In pituitary GH1 cells, a rat growth hormone-producing cell line, butyrate elicited a dose-dependent increase 
in cholera toxin receptors as measured by an increased binding of 1251-labeled cholera toxin to the intact cells. 
Butyrate did not alter the affinity of cholera toxin binding, the dissociation constant being 0.4 nM for both control 
and butyrate-treated cells. Despite the increased binding, the CAMP response to cholera toxin was strongly reduced 
after exposure to butyrate. This reduction was dose-dependent and with butyrate 1 - 5 mM, intracellular and 
extracellular (medium) CAMP levels were decreased by more than 70% in cells incubated for 24 h with 1 nM 
cholera toxin. Forskolin (30 FM) elicited a CAMP response similar to that found with the toxin, and a similar 
inhibition of CAMP was also found after incubation of GH1 cells with butyrate. Butyrate also affected basal 
CAMP levels which were reduced by 40-60% in cells cultured for 24-48 h with the fatty acid. In order to study 
whether butyrate influenced CAMP synthesis andlor CAMP degradation, adenylyl cyclase and phosphodiesterase 
activities were determined in control cells and in cells incubated for 24 h with cholera toxin or forskolin. Butyrate 
had a dual effect since, besides activating phosphodiesterase by more than twofold, it also inhibited the cyclase 
by 40 - 50% in all groups. The in vitro response of adenylyl cyclase to stimulatory (NaF) and inhibitory (carbachol 
and adenosine) effectors was also examined. The absolute activity of the cyclase was always 40 - 50% lower in 
the cells incubated with butyrate, but the percentage change of activity obtained in butyrate-treated and untreated 
cells was unaltered. In addition, ADP-ribosylation of the guanine nucleotide stimulatory component of the cyclase 
(Gs) was not affected in the cells incubated with butyrate. These results suggest that the catalytic (C) subunit of 
adenylyl cyclase and/or its interaction with the regulatory components might be altered in butyrate-treated GH1 
cells. 
The inhibition of the CAMP response in GH1 cells was accompanied by an inhibition of a biological action 
of the nucleotide, namely growth hormone (somatotropin) production which is primarily controlled by thyroid 
hormones in these cells. Forskolin alone did not affect the somatotropin levels but potentiated the growth hormone 
response to triiodothyronine. Butyrate produced a dose-dependent inhibition of this response, which was totally 
abolished at concentrations of butyrate higher than 1 mM. 
Butyrate exerts a variety of effects on growth, differen- 
tiation and metabolism in different types of cultured cells [I]. 
In neuroblastoma cells it has been noted that some of the 
butyrate effects could be mediated by an increase in intracellu- 
lar CAMP levels which might reflect an augmented adenylyl 
cyclase activity [2]. In HeLa cells butyrate induces a severalfold 
increase of 8-adrenergic receptor number and enhances 
agonist-stimulated adenylyl cyclase activity [3 - 51, by 
facilitating the ability of the regulatory components to couple 
to receptors [ 5 ] .  Although the molecular mechanisms by which 
the receptors and G proteins interact to stimulate the catalytic 
(C) subunit has not yet been elucidated, the interaction among 
the different components of the cyclase could be affected by 
changes in the structure of the cell membrane. 
Incubation with fatty acids is known to alter membrane 
structure and fluidity [6, 71, and butyrate specifically alters 
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glycolipid membrane composition in cells by inducing an in- 
crease in its ganglioside content [8, 91. As a consequence, 
butyrate induces an increase in cholera toxin receptors in 
several cell types [lo], since the toxin binds with high affinity 
to ganglioside GM1 in the cell membrane [ll].  These results 
prompted us to investigate the effects of butyrate on basal 
cyclic AMP levels and on the response to cholera toxin and 
forskolin in cultured growth-hormone-producing cells. Chol- 
era toxin stimulates adenylyl cyclase through ADP-ribosyla- 
tion of the guanine nucleotide stimulatory component (Gs) of 
the enzyme [12], whereas the diterpene forskolin appears to 
activate the cyclase by a direct interaction with its catalytic C 
subunit [13, 141. We reasoned that since butyrdte increases 
cholera toxin binding, it could enhance the response of the 
cyclase to the toxin but not to forskolin. However, our results 
indicate that in pituitary CHI cells, treatment with butyrate 
effectively blocked the response to both compounds, even 
though it increased cholera toxin binding to the cells. 
CHI cells produce and release growth hormone 
(somatotropin) to the medium, and CAMP has been described 
to influence somatotropin production by pituitary cells [15]. 
Therefore, we studied the effect of butyrate on basal 
684 
somatotropin production and on the response to forskolin. 
Since thyroid hormones are the main regulators of growth 
horinone gene expression in these cells 116, 171, we also 
analyzed the influence of the fatty acid on the combined re- 
sponse to forskolin and 3,5,3’-triiodo-~-thyronine. The data 
obtained demonstrated that butyrate inhibited the effect of 
forskolin on somatotropin production concomitantly with the 
inhibition of the cAMP response to the diterpene. 
EXPERIMENTAL PROCEDURES 
Materials 
Sodium butyrate, cholera toxin, carbachol and adenosine 
were obtained from Sigma. Forskolin was obtained from 
Calbiochem. ‘’’I was from Amhersam, [32P]NAD, [a- 
32P]ATP and [8-3H]cAMP were from New England Nuclear. 
All other reagents were obtained from Sigma or Merck and 
were of the maximal purity available. Culture media and sera 
were from Gibco, and culture flasks and plates were purchased 
from Nunc. 
Cell culture 
Pituitary GH1 cells were grown in monolayers as pre- 
viously described 116- 191 but using RPMI instead of Ham’s 
F10 medium. For the experiments the cells were inoculated 
at an initial density of 20000 cells/cm2 with RPMI medium 
containing 10% horse serum and 2.5% fetal calf serum; 24 h 
before the beginning of the experiments, the cells were shifted 
to a medium containing 10% serum treated with resin 
AGlX8 (Bio-Rad) and charcoal 1171. 
Cholera toxin binding 
Cholera toxin was iodinated with chloramine T 1201 to a 
specific activity of approximately 125 pCi/pg and purified in 
cellulose CF-11 columns. The cells were grown in 10-cm2 
plates and the binding assays were carried out in the cell 
monolayers in 1 ml serum-free medium containing 1251- 
labeled cholera toxin. Non-specific binding, determined in the 
presence of an excess cholera toxin (100 nM), was subtracted 
from the total binding to determine the amount of toxin 
specifically associated to the cells. The cultures were incubated 
for 45 min at 20-22”C, the medium was separated, and the 
cells washed three times with 4 ml ice-cold saline/phosphate 
buffer. The cells were then lysed in 0.4 M NaOH and trans- 
ferred to tubes for determination of radioactivity. The 
radioactivity of the medium was also determined and con- 
sidered to be the unbound ‘free’ toxin. An aliquot of the cell 
lysate was used for protein determination by the method of 
Lowry et al. 1211. All binding data were normalized to 100 pg 
cell protein and represent the mean of triplicate cultures which 
did not vary more than 5 - 10%. 
C A M P  determination 
The cells were grown in 2-cm2 multiwell plates and after 
different treatments medium was removed and cells were 
thoroughly rinsed with ice-cold saline. The CAMP was extract- 
ed from the cells with 5% perchloric acid and the acid extracts 
were neutralized with KHC03. The culture medium received 
the same treatment and was used to determine extracellular 
CAMP accumulation. lntracellular and medium cAMP con- 
tent was assayed by radioimmunoassay in acetylated samples 
1221 as previously described [I 81 using the immunoreagents 
obtained from New England Nuclear. 
Adeny1,vl cycluse assuy 
Confluent GHI cells grown in 75-cm2 flasks were detached 
from the flasks as described [23] and homogenized with a 
Dounce homogenizer in 1 ml of a buffer containing 27% (by 
mass) sucrose, 1 mM EDTA and 20 mM Na/Hepes pH 7.8. 
The cellular extracts contained approximately 1 mg protein/ 
ml. Incubations were carried out at 32°C for 10 min as 
previously described 1231 using 2 - 5 x lo6 cpm/assay of 
[32P]ATP. When present, 10 mM NaF, 10 pM carbachol, or 
10 pM adenosine were added during the incubations. The 
reaction was stopped and the [32P]cAMP formed was assayed 
by a modification [24] of the method of Salomon et al. [25]. 
A D  P-rihosylation 
A detailed description of the ADP-ribosylation assay has 
been given elsewhere 1231. The assays were carried out with 10 
p1 appropriately diluted homogenates to give a concentration 
of 1 mg/ml and [32P]NAD ( 2  - 5 x lo6 cpm) with or without 
600 pg cholera toxin/ml previously activated for 
30 min at 32 C with dithiothreitol and sodium dodecyl sul- 
phate in the conditions previously described 1231. After incu- 
bation for 30 min at 32”C, the reaction was stopped by ad- 
dition of 1 ml ice-cold 20% trichloroacetic acid. The trichloro- 
acetic-acid-insoluble material was washed with ethyl ether [23] 
and the samples were analyzed for incorporation o ~ [ ~ ~ P ] A D P -  
ribose into CI subunits of C H I  cells by resuspending in 20 p1 
Laemmli’s sample buffer 1261 at room temperature and 
loading onto 11 % SDS/polyacrylamide slab gels. Electro- 
phoresis was performed according to Laemmli, and the gels 
were dried and autoradiographed to visualize bound 32P. 
Phosphodiesterase assay 
Cyclic nucleotide phosphodiesterase was measured using 
methods described elsewhere [27, 281. The assay mixture, in a 
final volume of 100 p1, consisted of 20 mM Tris/HCl, 1 mM 
CI2Mg, 1 mM EGTA, 60 units 5’-nucleotidase, 100 pg soybean 
trypsin inhibitor, 100 pM CAMP, approximately 60000 cpm 
[3H]cAMP, and an appropriate dilution of the cell 
homogenates. The mixture was incubated for 20 min at  30 “C 
in the presence or absence of 0.2 mM CaCI,. The reaction was 
stopped by addition 1 ml of activated AGIX8 resin (Bio- 
Rad) suspended 1 : 3 in distilled water. After centrifugation at 
1000 x g for 15 min, 3H was measured in a 0.4-ml aliquot of 
the supernatant. The hydrolyzed cAMP was calculated by 
subtracting blank values obtained with boiled extracts, and 
applying the adenosine retention power of the resin as a cor- 
rection factor. Degradation of the substrate was always less 
than 20% of the initial concentration. 
Quantification of somato tropin production 
To study the growth hormone (somatotropin) response, 
the cells were grown in 2-cm2 multiwell plates with 1 ml 
medium. After a 24-h incubation in the presence or absence 
of 1 mM butyrate, the cells received 5 nM 3,5,3’-triiodo-1,- 
thyronine and/or 30 pM forskolin. After 24 h, the medium 
was saved and the cells were washed with saline and used for 
quantification of cell protein 1211. In GH1 cells the accumu- 
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Fig. 2 .  Effect of butyrate on L251-labeled cholera toxin binding to G H l  
cells. 'The cells were incubated with the concentration of butyrate 
indicated for 24 h. Binding was determined by incubating the cells 
with 0.12 nM '251-labeled cholera toxin (['251]ChT) as described 
under Experimental Procedures. In this and in thc following figures 
each data point represents the mean f SD of triplicate cultures which 
normally did not vary more than 10- 25% 
lation of somatotropin in the medium reflects the rate of 
somatotropin synthesis, since they do not accumulate the hor- 
mone intracellularly and somatotropin is stable in the culture 
medium [16, 171. Somatotropin was determined by means 
of a specific rddioimmunoassay using the immunoreagents 
provided by the NIAMDD, and all samples were assayed at 
least at two different dilutions. 
RESULTS 
Effect ofbutyrate on cholera toxin binding to GHI cells 
Fig. 1 shows the effect of different concentrations of buty- 
rate on binding of 1251-labeled cholera toxin. Butyrate pro- 
duced a dose-dependent increase of cell-associated radio- 
activity. A half-maximal effect was found at approximately 
1.6 mM, and the maximal increase (1.9-fold over control 
levels) was found at 5 mM. This effect was due to an increase 
in specific binding with no change in non-specific binding (less 
than 4% of the total), or in toxin degradation (less than 7%). 
Binding studies were also performed in untreated cells and in 
cells treated with 1 mM butyrate in the presence of increasing 
concentrations of 1251-labeled cholera toxin. The inset in Fig. 2 
shows that butyrate increased binding at all concentrations 
examined. When the binding data were analyzed by the 
method of Scatchard, linear plots were found (Fig. 2). There 
was n o  significant difference in the slopes but the maximal 
binding capacity increased by 33% in the butyrate-treated 
cells. Therefore, butyrate did not alter the affinity of cholera 
toxin binding (Kd = 0.4 nM in both groups) but increased the 
number of binding sites. 
Influence ofbutyrate on the C A M P  response 
to cholera toxin and forskolin 
Fig. 3 illustrates the effect of incubation with increasing 
concentrations of butyratc on the stimulation of cAMP levels 
by 1 nM cholera toxin. The toxin caused a sevenfold increase 
in intracellular CAMP, and butyrate at concentrations higher 
than 0.1 mM caused a dose-dependent reduction on the re- 
sponse to cholera toxin (Fig.3A). With butyrate 1-5 mM, 
cAMP was almost as low as in untreated cells. The fatty acid 
also produced a similar decrease of uninduced cAMP levels 
which were reduced by more than 60% with butyrate > 1 mM. 
B(frnoV100pg protein) 
Fig.2. Scatchard plot of i251-labeled cholera toxin binding. GHI cells 
were incubated with 1 mM butyrate for 24 h. These cells, along with 
control cells which did not receive butyrate, were incubated with 
different concentrations of '251-labeled cholera toxin (['251]ChT) and 
the radioactivity specifically associated to the cells was determined. 
The inset represents the association curve of toxin binding in both 
groups of cells. Control cells ( 0 ) ;  butyrate-treated cells (0); 
B/F = ratio of bound "'I/free lZ5I  
The extracellular cAMP (Fig. 3 B) paralleled the intracellular 
CAMP, and butyrate also produced a dose-dependent inhi- 
bition of cAMP accumulation into the medium. In agreement 
with our previous results in GHI  cells [18, 191, after 24 h, 
intracellular cAMP represented less than 10% of the cAMP 
released by the cells into the culture medium. 
Fig. 4 shows the inhibitory effect of 1 mM butyrate on the 
response to 1 nM and 100 nM cholera toxin. In agreement 
with our previous results [18, 191,O.l nM cholera toxin elicited 
a greater cAMP response than that produced by the highest 
concentration. Basal cAMP decreased by 40% and the re- 
sponse to the toxin was inhibited by more than 60% in the 
cells incubated with butyrate. Although this inhibition was 
less marked than that obtained in Fig. 3, where the cells had 
been pre-incubated with butyrate for 24 h, these results show 
that pre-incubation with the fatty acid is not required in order 
to decrease the response to the toxin. 
That the inhibitory effect of butyrate is not restricted to 
stimulation with cholera toxin is illustrated in Fig. 5, where 
the effect of butyrate on the cAMP response to forskolin 
was examined: 5 pM and 30 pM forskolin stimulated cAMP 
production to a similar extent as 1 nM cholera toxin; cAMP 
accumulation was also greatly diminished in the presence of 
1 mM butyrate. 
We next examined the reversibility of the effect of butyrate 
on basal and cholera-toxin-stimulated CAMP. Fig. 6 shows the 
time course of cAMP accumulation in the medium from cells 
which wcre pre-incubated for 24 h with or without 1 mM 
butyrate and were then washed free of the fatty acid. In 
untreated cells CAMP accumulated rapidly after incubation 
with the toxin and remained constant over 5 - 20 h. In butyr- 
ate-preincubated cells, cAMP levels were lower during the 
period examined; 2 h aftcr removal of butyrate, cAMP ac- 
cumulation in response to cholera toxin was 20-fold lower in 
the cells previously exposed to the fatty acid. The difference 
became gradually smaller, and 20 h after butyrate removal 
cAMP levels were 4-fold lower than in untreated cells. In 
unstimulated cells, CAMP levels were also 30 - 50% lower in 
cells previously exposed to the fatty acid during the whole 
experimental period. 
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Fig.4. Ej'ect ofhutyrate and cholera toxin on CAMP levels. GHI cells 
were incubated for 24 h with 0, 1 and 100 nM cholera toxin in the 
absence (open bars) or the presencc (stippled bars) of 1 mM butyratc, 
and intracellular (A) and extracellular (B) cAMP were determined 
Forskolin (pM) 
Fig. 5.  Influence ofhutyrate on the c A M P  response to jorskolin. The 
cells were incubated with the concentrations of forskolin indicated in 
the absence (open bars) or presence (stippled bars) of 1 mM butyrate. 
Intraccllular (A) and medium (B) CAMP were dctcrmined after 24 h 
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Fig.6. Reversihility of the effect o j  butyrate. GHI cells were pre- 
incubated for 24 h in the presence (n, 0) or absence ( W ,  0 )  of 
1 mM butyrate. The cultures were then washed free of butyrate (time 
0 in the figure) and rcceivcd medium alone (0, 0 )  or 1 nM cholera 
toxin (0, W). CAMP accumulation into the medium was determined 
at  the times indicated in the figure 
Adenylyl cyclase und phosphodiesterase activity 
The decreased CAMP response in the cells incubated with 
butyrate may occur as a result of a decrease in cAMP syn- 
thesis, an increase in degradation, or by a combination of 
both effects. To differentiate between these possibilities, 
adenylyl cyclase and phosphodiesterase activity were deter- 
mined in GH1 cells incubated with and without butyrate. 
Fig.7 shows the influence of butyrate on adenylyl cyclase 
activity. Basal enzyme levels were decreased by approximately 
40% in cells treated with 1 mM butyrate for 24 h. Forskolin 
(30 pM) and cholera toxin (1 nM) induced an 8-10-fold 
increase in adenylyl cyclase activity over basal levels, and 
butyrate also decreased activity by 50% under these con- 
ditions. 
NaF increased enzyme activity by more than twofold in 
homogenates from untreated or forskolin-treated cells, 
whereas it slightly decreased activity in the cells incubated 
with the toxin. Under all conditions, the activity of the enzyme 
was reduced by 30-40% in the homogenates from the cells 
incubated with butyrate. Carbachol and adenosine decreased 
adenylyl cyclase by 40- 50% in all groups; the inhibitory 
effect of butyrate was again observed in the presence of these 
compounds. It is important to observe that, although the 
absolute activity of the cyclase was always lower in the cells 
incubated with butyrate, treatment of cells with the fatty acid 
interfered little with the degree to which the different effectors 
act, the percentage of the stimulation or inhibition being ap- 
proximately the same in homogenates of control and butyrate- 
treated cells. 
In order to ADP-ribosylate G subunits, GH1 cell extracts 
were incubated with [32P]NAD and activated cholera toxin 
(Fig. 8). When analyzed by polyacrylamide gel electrophoresis 
three main radioactive bands (120, 45 and 24 kDa) were ob- 
served. The 45-kDa polypeptide was specifically labeled by 
the toxin and therefore represents the a component of Gs. 
Densitometry of the autoradiogram did not demonstrate 
changes in the extent of labeling of Gs in the cells treated 
with butyrate. As expected [23], previous exposure of the cell 
cultures to the toxin resulted in an essentially complete dis- 
appearance of sites susceptible to subsequent in vitro ADP- 
ribosylation with [32P]ADP-ribose. Pre-incubation with the 
toxin also decreased incorporation into the 120-kDa acceptor 
which could represent nuclear poly(ADP-ribose) synthetase, 
in agreement with our previous data showing that incubation 
of GHI cells with cholera toxin for 24 h decreases nuclear 
ADP-ribosylation [I 91. The 24-kDa band, that represents the 
self ADP-ribosylated A subunit of the toxin [29], was not 
altered by any treatment. 
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Fig. 7. Influence of'butyrate on basal and stimulated adeny1,vl cyclase activity. GH1 cells were incubated for 24 h with (stippled bars) or without 
(open bars) 1 mM butyrate. The cultures received no additions (control), 30 pM forskolin or 1 nM cholera toxin. Adenylyl cyclase was 
determined as described under Experimental Procedures and when indicated 10 mM NaF, 10 pM carbachol (Cchol) or 10 pM adenosine 
(Ado) were added during the assay to the cell homogenates 
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Fig. 8. ADP-ribosylation of Gs by cholera toxin in intact and hutyrate- 
treated GH1 cells. Cells were treated or not with 1 mM butyrate for 
24 h in the presence or absence of 1 nM cholera toxin. The cells were 
homogenised and tested for ADP-ribosylation with activated cholera 
toxin and [32P]NAD. The [32P]ADP-ribosylated proteins were separ- 
ated by SDSjPAGE and identified by autoradiography. The apparent 
molecular masses of standard proteins electrophoresed in parallel 
lanes are given. Lanes 1 and 2, control cells; lanes 3 and 4, butyrate- 
treated cells; lanes 5 and 6, cholera-toxin-treated cells; lanes 7 and 8, 
butyrate + cholera-toxin-treated cells 
Phosphodiesterase activity is shown in Fig. 9. Incubation 
with either forskolin or cholera toxin for 24 h did not alter 
cyclic nucleotide phosphodiesterase activity in GHI cells. 
However, butyrate produced a more than twofold increase in 
activity in all experimental groups. 
Injluence of butyrate on the biological action of CAMP 
We then examined whether or not the decrease in cAMP 
levels caused by butyrate was accompanied by an inhibition 
in the biological action developed by the nucleotide in GH1 
cells. In Fig. 10 somatotropin production by GH1 cells incu- 
bated for 24 h with increasing concentrations of butyrate 
and then exposed for an additional 24 h period to 5 nM 
triiodothyronine and/or 30 pM forskolin is shown. In the 
absence of thyroid hormones, neither butyrate nor forskolin 
significantly influenced somatotropin levels. Triiodothy- 
ronine elicited an 1 1-fold stimulation of somatotropin pro- 
duction, and cAMP potentiated the effect of triiodothyronine, 
Fig. 9. Effect uf butyrate on phosphodiesterase activity. The high K ,  
phosphodiesterase was determined in the same cells as those used in 
Fig.7. C, control; FK, 30 pM forskolin; ChT, 1 nM cholera toxin. 
Stippled bars: butyrate-treated cells 
*4?L-d 
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Fig. 10. Influence of butyrate on the s~matotr(ipin response to forskolin 
and triiodothyronine. CHI cells were incubated with the concen- 
trations of butyrate inducated for 24 h. The cultures then received the 
same concentrations of butyrate with (0 ,  W )  or without (0, 0) 
30 pM forskolin and 5 nM 3,5,3'-triiodo-~-thyronine (0, W). 
Somatotropin (GH) production was examined 24 h later as described 
under Experimental Procedures 
increasing somatotropin 20-fold over control levels. Butyrate 
did not affect the response to triiodothyronine at concen- 
trations below 1 mM, whereas at 3 mM significantly decreased 
it. Butyrate produced a dose-dependent inhibition of 
forskolin-stimulated somatotropin production. The dose/re- 
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sponse of this inhibitory effect of the fatty acid was almost 
identical to that found for the inhibition of CAMP production 
(Fig. 3) and with concentrations 1 mM and higher the response 
to forskolin was totally blocked. 
DISCUSSION 
In this study, we have examined basal CAMP and its re- 
sponse to cholera toxin and forskolin in pituitary GH1 cells 
incubated with butyrate. Our results show that, in control 
non-stimulated cells, basal CAMP levels were significantly de- 
creased after exposure to butyrate. This contrasts with the 
reported elevation of CAMP levels in neuroblastoma cells 
incubated with butyrate [2] and indicates the specificity of the 
effect of the fatty acid in the different cell types. 
Butyrate has been described as increasing cholera toxin 
binding in other cell types [I 01 due to an increase in ganglioside 
GM1 content, the reported toxin receptor [ll].  The number 
of cholera toxin receptors found by us in untreated GH1 cells 
is at least tenfold higher than that described for HeLa or C6 
cells, and similar to that found in Friend cells [lo]. We have 
provided evidence that butyrate causes an increase in cholera 
toxin receptors in GH1 cells, although this increase was less 
marked than that observed in HeLa or C6 cells [lo]. This also 
occurred in Friend cells, thus suggesting that the quantitative 
effect of butyrate could depend on the initial concentration of 
receptors. On the other hand, the affinity of the toxin for 
control and butyrate-treated GHI cells was identical, and 
appeared to be similar to that described in HeLa cells [lo]. 
The increase in the number of binding sites without changes 
in affinity suggests that the concentration of GM1 ganglioside 
is increased in the membranes of GH1 cells exposed to the 
fatty acid. 
After the initial high affinity binding of the B protomer 
subunit of the toxin to GM1, the A protomer component 
is internalized and exerts its effect by catalyzing the ADP- 
ribosylation of the stimulatory Gs component of the cyclase 
[12]. Therefore, it was expected that the increase in cholera 
toxin binding brought about by butyrate must be followed by 
an increased modification of Gs and by a subsequent elevation 
of adenylyl cyclase activity and CAMP synthesis. However, 
our results clearly show that in butyrate-treated GH1 cells, 
CAMP levels are strongly decreased, rather than increased, in 
response to cholera toxin. The effect of butyrate was found to 
be dose-dependent and to be more accentuated when the cells 
were pre-incubated with butyrate before exposure to the toxin 
than when both compounds were added simultaneously to the 
cells. In addition, the reversal of the effect of the fatty acid 
was slow, suggesting that a direct ‘allosteric’ effect of the 
butyrate molecule on some of the adenylyl cyclase components 
is very unlikely. 
To test whether the inhibition of CAMP formation could 
reflect a decreased presence of a functional Gs, we also tested 
the CAMP response to forskolin which activates the cyclase 
by a direct interation with its catalytic subunit [I31 and is 
capable of stimulating CAMP in cells lacking Gs [30]. The 
data obtained indicated that a clearly diminished response to 
forskolin was also found in butyrate-treated cells and that, 
therefore, a predominant effect of butyrate on Gs is unlikely. 
The presence of unaffected Gs in homogenates of butyrate- 
treated cells was also demonstrated by ADP-ribosylation, 
since [32P]ADP-ribose incorporation to the CI subunit was not 
different from that found in control GH1 cells. In agreement 
with that found in other pituitary cells [23], treatment of intact 
cells with cholera toxin resulted in modification of essentially 
all Gs molecules as shown by the inhibition of in vitro 
[32P]ADP-ribose incorporation; this also occurred in the cells 
incubatcd with butyrate. 
A decreased accumulation of CAMP could be caused by 
an increase in phosphodiesterase activity and/or by an inhi- 
bition of the adenylyl cyclase. We found that butyrate had 
a dual effect in GH1 cells, inhibiting CAMP synthesis and 
enhancing CAMP degradation, which results in an additive 
effect and a marked inhibition of CAMP levels. Phospho- 
diesterase activity was not altered by cholera toxin or forskolin 
in GH1 cells, whereas it increased by more than twofold in 
the cells treated with the fatty acid. In contrast, butyrate 
significantly decreased basal levels of adenylyl cyclase activity 
and, as expected, treatment with cholera toxin and forskolin 
strongly activated the cyclase. The enzyme from butyrate- 
treated cells retained its susceptibility to become activated by 
both compounds, but the absolute activity was decreased to 
half the values found in the cells which were not exposed to 
the fatty acid. 
A similar situation was found when NaF was present in 
the assay. NaF was an effective stimulator of the cyclase in 
control cells and in cells incubated with forskolin, whereas 
after treating the cells with cholera toxin resulted in an inhi- 
bition of activity. This has been interpreted as the result of the 
dual effect of fluoride to activate Gs (stimulatory) and Gi 
(inhibitory) at the same time [23, 311. Since, in the cells treated 
with cholera toxin, Gs is fully activated, the inhibitory effect 
of NaF becomes apparent. The effect of butyrate was equally 
visible in the absence and the presence of stimulatory regu- 
lation by NaF and, although under all conditions the response 
in terms of percentage of the respective control remained 
unaltered, a reduction of cyclizing activity was always ob- 
served. 
To test whether activation of Gi could be responsible for 
the inhibitory action of butyrate on the cyclase, the effect 
of inhibitory hormones was also examined. Carbachol and 
adenosine are able to decrease cyclase activity in other pitu- 
itary cells [23, 321 and they also decreased activity by 40- 
50”h when added to homogenates of GH1 cells. Although 
absolute activities were again decreased in butyrate-treated 
membranes as compared with control membranes in all 
groups, the relative inhibition of activity attainable by acti- 
vation of the Gi pathway with either carbachol or adenosine 
remained unaltered in homogenates from cells incubated with 
butyrate. This suggests that activation of Gi probably does 
not play a fundamental role in the inhibitory effect of the fatty 
acid. 
Taken together, our results show that, whereas cyclase 
activity is decreased in butyrate-treated cells, when analyzed 
in terms of percentage of control, the effectiveness with which 
inhibitory or stimulatory effectors of the cyclase G compo- 
nents act is unaffected. This suggests that a decrease in the 
functional catalytic C subunit and/or a change in its interac- 
tion with the regulatory components could be responsible for 
the observed effect. An alteration in the coupling among the 
different components of the cyclase would not be unexpected 
in cells incubated with butyrate, since this compound appears 
to induce a variety of biochemical changes in the cell mem- 
brane [I] and incubation of cultured cells with fatty acids 
alters membrane lipid composition and, as a consequence, 
membrane fluidity [6,7]. In this respect it is interesting to note 
that butyrate increases the responsiveness of HeLa cells to 
catecholamines [3 - 51. In these cells butyrate induces large 
increases in f i  receptor number and qualitative changes in the 
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regulatory component that facilitate its ability to couple to 
receptors but do not alter its ability to respond to other non- 
hormonal effectors [ S ] .  Therefore, these observations and the 
effect of butyrate in GH1 cells may be the consequence of 
a direct modification in the cyclase components or may be 
indirectly caused by changes in other membrane components 
which in turn modulate cyclase activity. 
Pituitary GH1 cells and other related cell lines have been 
proven to be a very useful model for studying hormonal regu- 
lation of somatotropin production. In these cells tri- 
iodothyronine regulates somatotropin gene expression [17], 
and other hormones and factors modulate the response to 
thyroid hormones [33 - 361. Among the physiological com- 
pounds that regulate somatotropin, growth-hormone-releas- 
ing hormone (GRH) acting through an elevation of intracel- 
Mar cAMP appears to increase somatotropin synthesis in 
pituitary cells [l 51. We examined the effect of cAMP on soma- 
totropin production by CHI cells. Incubation with forskolin 
instead of cholera toxin was chosen, since the toxin decreases 
thyroid hormone receptor levels, whereas the diterpene does 
not affect this receptor [18]. Our results show that cAMP by 
itself does not induce somatotropin production, but potent- 
iates the effect of triiodothyronine. This is similar to that 
found with glucocorticoids, other important regulators of 
somatotropin gene expression [33, 341. Butyrate has been de- 
scribed to influence somatotropin production by cultured 
pituitary cells [ 3 5 ,  361 and we found that with concentrations 
of butyrate higher than 3 mM the response to triiodothyronine 
is significantly decreased. Since butyrate inhibits the cAMP 
response to forskolin, the fatty acid should also inhibit the 
somatotropin response caused by forskolin. Our results indi- 
cate that the response to forskolin was in fact abolished in the 
presence of butyrate, thus showing that the decreased cAMP 
response is reflected in the inhibition of the biological function 
of the nucleotide in somatotropin-producing cells. 
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